Arvinas (ARVN) Set to Release Earnings on Wednesday

Arvinas (NASDAQ:ARVN) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Arvinas to post earnings of ($0.8671) per share and revenue of $16.82 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of ($0.37) by $2.95. The firm had revenue of $249.70 million for the quarter, compared to the consensus estimate of $60.71 million. The company’s revenue for the quarter was up 1014.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.84) EPS. On average, analysts expect Arvinas to post $0.05 EPS for the current fiscal year and ($3.37) EPS for the next fiscal year.

Arvinas Trading Up 1.9%

Shares of Arvinas stock opened at $7.45 on Wednesday. Arvinas has a 12-month low of $6.74 and a 12-month high of $14.51. The firm’s 50-day moving average price is $8.19 and its two-hundred day moving average price is $9.77.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ARVN. Wedbush upped their price target on shares of Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Morgan Stanley set a $10.00 price target on shares of Arvinas in a research report on Monday, August 10th. Wells Fargo & Company reissued an “equal weight” rating and issued a $11.00 price objective (down from $15.00) on shares of Arvinas in a research note on Tuesday, August 4th. Zacks Research upgraded shares of Arvinas from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th. Finally, Evercore set a $14.00 target price on Arvinas in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Arvinas currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.40.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.